About Pantesin
Pantethine is the disulfide dimer of pantetheine, a direct precursor of coenzyme A — and it is pharmacologically distinct from pantothenic acid (vitamin B5). B5 supplementation alone does not lower lipids; pantethine does, likely via inhibition of hepatic cholesterol and fatty acid synthesis through CoA-mediated effects on HMG-CoA reductase and acetyl-CoA carboxylase. McRae 2005 (Nutr Res 25:319–33) pooled 28 trials in 646 hyperlipidemic subjects at a median 900 mg/day and reported ~15% total cholesterol and ~20% LDL reductions by month 4, plus ~11% HDL increase by month 3. Evans 2014 (PMID 24600231, Vasc Health Risk Manag 10:89–100) confirmed modest but significant LDL and non-HDL reductions vs placebo at 600–900 mg/day over 16 weeks in low-to-moderate CV risk adults eligible for statins. Effect size is real but smaller than statins, and the pooled trials are mostly small and industry-adjacent — moderate evidence, not high. Do not score pantethine against B5 dose ranges; sub-600 mg doses are sub-therapeutic for the lipid indication.
What Pantesin supports
- Modest LDL and total cholesterol reduction at 600–1,200 mg/day
- May raise HDL cholesterol over 3+ months of use
- Distinct lipid-active form, not a B5 substitute
How much Pantesin to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
600–1200
mg
Lipid-management RCTs use 600–1,200 mg/day in divided doses (median 900 mg/day). Below 600 mg/day there is no clinical evidence of lipid effects; this is not interchangeable with B5 dosing.
Clinical evidence
Moderate clinical evidence. Strongest evidence: McRae 2005 pooled review of 28 trials (n=646) plus Evans 2014 RCT (PMID 24600231) — modest LDL reduction at 600–1,200 mg/day in hyperlipidemic adults
Examine.com